[ Disclaimer: The information on GoldBamboo for any particular treatment, medicine, drug, or herbal product might be missing or incomplete, and should never be used as a single source of knowledge. GoldBamboo generally has links to authoritative sites displayed toward the bottom of each topic page under the heading "Resources". ]
Developmental Disabilities & Disorders |
Developmental Disabilities |
Clinical Trial: A Laboratory Model for Heroin Abuse Medications - 8
This study is no longer recruiting patients.
Purpose
The purpose of this study is to evaluate the effects of treatment medications (methadone, buprenorphine, LAAM, naltrexone, naltrexone microcapsules, and methoclocinnamox) on I.V. and smoked heroin self-administration."
| Condition | Treatment or Intervention | Phase |
|---|---|---|
| Heroin Dependence Opioid-Related Disorders Substance-Related Disorders | Drug: Methadone | Phase II |
MedlinePlus related topics: Drug Abuse; Heroin Abuse; Prescription Drug Abuse
Study Type: Interventional
Study Design: Treatment, Uncontrolled
Official Title: A Laboratory Model for Heroin Abuse Medications
Expected Total Enrollment: 37
Study start: August 1995; Study completion: August 1997
Eligibility
Ages Eligible for Study: 18 Years - 45 Years, Genders Eligible for Study: Both
Criteria
Location Information
New York
Columbia University, New York, New York, 10023, United States
Herbert Kleber, M.D., Principal Investigator, New York State Psychiatric Institute
More Information
Record last reviewed: August 1995
Last Updated: November 18, 2004
Record first received: September 20, 1999
ClinicalTrials.gov Identifier: NCT00000273
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2005-04-08
Source: ClinicalTrials.gov
Cache Date: April 9, 2005
Resources
- Accommodations for People with Mental Retardation (Job Accommodation Network)
- Adopting Children with Developmental Disabilities (National Adoption Information Clearinghouse, ACYF, ACF, HHS)

Not Signed In -


